Shengtai Pharmaceutical's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Shengtai Pharmaceutical in the third quarter 2013?
Shengtai Pharmaceutical, Inc. achieved a return on average equity (ROE) of 0.89 % in its third quarter 2013, this is above SGTI's average return on equity of 0%.
Shengtai Pharmaceutical, Inc. shareholder's equity over the 12 months ending in its third quarter 2013 are valued at $63 million

Within the Biotechnology & Pharmaceuticals industry Shengtai Pharmaceutical, Inc. achieved the highest return on equity. While the total ranking for ROE unchanged, relative to the second quarter 2013 at no. .

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2013) III. Quarter	(Dec 31 2012) II. Quarter	(Sep 30 2012) I. Quarter	(Jun 30 2012) IV. Quarter	(Mar 31 2012) III. Quarter
Y / Y Equity Change	3.4 %	4.34 %	2.33 %	4.55 %	-
Y / Y Net Income Change	7.04 %	-	-77.78 %	-	-95.74 %
Net Income (TTM) in Millions	1	1	0	1	4
Return On Equity (TTM)	0.89 %	0.89 %	0.37 %	1.49 %	7.17 %
SGTI's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	64	64	62	62	62
Seq. Equity Change	0.47 %	2.52 %	0.12 %	0.26 %	1.39 %
Seq. Net Income Change	-59.72 %	33.07 %	-	-	-

Back to SGTI Management Effectiveness >> SGTI's 5 Years Annual ROE >> Compare SGTI ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

SGTI Annual Return On Equity	(Jun 30 2012) 2012
Total Equity in Millions	62	0	0	0	0
Y / Y Equity Change	-	-	-	-	-
Net Income in Millions	1	0	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	1.72 %	-	-	-	-

Back to SGTI Management Effectiveness >> SGTI's 5 Years Annual ROE >> Compare SGTI ROE to its Competitors

Annual Roe Comment

In 2012 ROE improved to 1.72 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SGTI's' Return on Equity at Yahoo Finance
SGTI's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SGTI's Competitors
Subscribers only: Roe for Shengtai Pharmaceutical's Suppliers
Subscribers only: Return On Equity for SGTI's Customers

Companies with similar Return On Equity at Mar 31 2013, within Healthcare Sector	ROE
Biocept Inc	2.09 %
Harvard Bioscience Inc	1.91 %
Wright Medical Group N v	1.65 %
Immucell Corporation	1.50 %
Cumberland Pharmaceuticals Inc	1.21 %
Tenet Healthcare Corp	1.06 %
Viskase Holdings inc	0.51 %
Heska Corporation	0.48 %
Nuvasive Inc	0.48 %
Masimo Corp	0.22 %

Date modified: 2026-09-08T15:21:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.